AI Drug Discovery Consortium Joins Forces with NVIDIA

CRAIG RHODES | August 8, 2019

article image
Pharmaceutical companies have traditionally kept their data close to the vest because collaborations side effects may include compromising intellectual property and losing the edge over competitors. But sharing data has major perks. The more data a pharma company has at its disposal, the better equipped its researchers are to quickly identify and develop promising new drugs. This can ultimately improve drug candidate success rates and reduce treatment costs.

Spotlight

Riverside Healthcare

Riverside Medical Center is located in Kankakee, IL and is part of Riverside Healthcare, a fully integrated healthcare system serving the needs of individuals and communities throughout the counties of Kankakee, Iroquois, Will, Grundy and beyond. As part of the system, Riverside Medical Center, a 312-bed hospital, provides a full scope of inpatient and outpatient care and is a nationally recognized, award-winning Level II Trauma hospital with nationally-leading programs in heart care, cancer care, neurosurgery and orthopedics. Its reputation for nursing excellence has made Riverside the area's only Magnet® Recognized hospital. Because Riverside's clinical performance ranks them among the top 5 percent of hospitals nationwide, Healthgrades has named them a Distinguished Hospital for Clinical Excellence Award, and Truven Health Analytics presented them with the 100 Top Hospitals® award.

OTHER ARTICLES

New Dimensions of Clinical Trial Optimization

Article | April 20, 2021

For much of the past three decades, even as methodologies for clinical trial design have advanced and refined, the idea of the optimized clinical trial has centered on optimal patient samples, target enrollment rates, and generally the most efficient uses of scarce resources in the form of patients. Yet anyone who has had to design and optimize a clinical trial, knows that trial optimization occurs within an ecosystem of choices; a series of choices that stretch from the time it takes to implement a clinical trial and submit clinical data for analysis, to general concerns about the cost and power of a clinical trial. A true clinical trial optimization process would try to unify a number of these choices into a single framework for trial optimization. The complexity of clinical trial optimization comes from the need to align priorities on the one hand, and to understand opportunities on the other. We know that at a very general level, clinical operations specialists benefit from simplicity in clinical trial design, and that commercial teams prefer shorter clinical trials to longer ones. We also know that the statistical design of a clinical trial can influence both simplicity and duration. Yet how many sponsors have their clinical operations and commercial teams, sit with their R&D teams to review various statistically nuanced design options? For many sponsors, the reason this process does not occur as often as it should, is because the nuanced statistical parameters of a clinical trial design are very difficult to communicate to non-statisticians. Yet a trial optimization tool like Solara, equipped with data visualizations and the ability to see tradeoffs intuitively, can overcome this challenge. The real challenge is often convincing the non-statistician that they have a stake in clinical trial design. Cytel recently had a client that thought it needed a sample size re-estimation design, because it had a very strict limit on the number of patients it could enroll. After a few hours of working with Solara, though, a statistician discovered that a much simpler Group Sequential Design would deliver comparable power using about the same number of patients. The gains from the more complex design were minimal from the optimization perspective, when understood as the eco-system of choices. Similarly, most commercial teams pressure their clinical trial designers to have the most accelerated clinical trial imaginable, but as we all know, the longer the clinical trial the more likely there will be a higher number of events that demonstrate the effectiveness of a new medicine. So commercialization teams have a stake in longer clinical trials, even when their rule of thumb is to shorten them. Therefore, it is absolutely essential to communicate the benefits of various statistical designs to multiple stakeholders in a way that makes tradeoffs clear. Aligning on priorities early during the clinical trial design process is essential to selecting the optimal clinical trial. Yet for this statisticians need to be equipped for both a strategic and communicative role in the R&D process.

Read More

Coronavirus Pandemic Brings Hundreds Of U.S. Clinical Trials To A Halt

Article | April 11, 2020

Rene Roach fired off a quick email in late March for an update on a colorectal cancer clinical trial for which she hoped to qualify. Worried about the coronavirus, she asked, almost as an afterthought, whether the study had been put on hold because of the pandemic.The answer crushed her: It had been. "That's when COVID-19 shut down everything," says Roach, 50, of Germantown, Md. Roach assumed that there would be workarounds for patients like her, who have stage IV cancer. These patients often depend on clinical trials as their best chance to knock cancer out when other therapies have failed. For now, she's being treated with traditional chemotherapy, but she was counting on the drug cocktail from the clinical trial. She figures if chemo was going to rid her body of cancer for good, it would have done so already.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Spotlight

Riverside Healthcare

Riverside Medical Center is located in Kankakee, IL and is part of Riverside Healthcare, a fully integrated healthcare system serving the needs of individuals and communities throughout the counties of Kankakee, Iroquois, Will, Grundy and beyond. As part of the system, Riverside Medical Center, a 312-bed hospital, provides a full scope of inpatient and outpatient care and is a nationally recognized, award-winning Level II Trauma hospital with nationally-leading programs in heart care, cancer care, neurosurgery and orthopedics. Its reputation for nursing excellence has made Riverside the area's only Magnet® Recognized hospital. Because Riverside's clinical performance ranks them among the top 5 percent of hospitals nationwide, Healthgrades has named them a Distinguished Hospital for Clinical Excellence Award, and Truven Health Analytics presented them with the 100 Top Hospitals® award.

Events